Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

This study has been completed.
Synteract, Inc.
Information provided by (Responsible Party):
Dynavax Technologies Corporation Identifier:
First received: January 14, 2009
Last updated: August 23, 2016
Last verified: August 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: February 2010
  Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)